A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes

NCT07357740 on ClinicalTrials.gov · last registry update 2026-07-09

Withdrawn before anyone was enrolled. Due to report 25 August 2027, alongside 40 other tracked readouts that quarter. Primary outcome, as filed: Change in glycated haemoglobin (HbA1c). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: WITHDRAWN
Phase: P2
Drug: semaglutide
Ozempic, Rybelsus, Wegovy
Sponsor: Novo Nordisk A/S
Sponsor type: Industry
Enrollment: 0
Started: 2026-08-27
Primary completion: 2027-08-25 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in glycated haemoglobin (HbA1c)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.